Lin SM, Cao LQ, Zhang ZH, Xiao JB, Li Q. EGCG enhances 5-fluorouracil-induced cell growth inhibition in human hepatocellular carcinoma cell line BEL-7402.
Shijie Huaren Xiaohua Zazhi 2011;
19:619-623. [DOI:
10.11569/wcjd.v19.i6.619]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate whether epigallocatechin-3-gallate (EGCG) enhances 5-fluorouracil (5-FU)-induced cell growth inhibition in human hepatocellular carcinoma cell line BEL-7402 and to explore potential mechanisms involved.
METHODS: MTT assay was used to evaluate cell viability. Western blotting analysis was performed to detect protein expression, and small interfering RNA was used to suppress COX-2 expression. ELISA assay was applied to test the release of prostaglandin E2 (PGE2).
RESULTS: Treatment with different concentrations of EGCG (5, 10, 25, or 50 mmol/L) significantly inhibited the growth of BEL-7402 cells compared with control cells (treated with 0.1% DMSO, all P < 0.05). When cells were treated with 10 mmol/L 5-FU in combination with either 5, 10, 25, or 50 mmol/L EGCG, the percentages of viable cell significantly decreased when compared with cells treated with each drug alone, suggesting a synergistic effect between the two drugs. Moreover, EGCG down-regulated the expression of COX-2 and reduced the release of PGE2 in BEL-7402 cells.
CONCLUSION: EGCG enhances 5-FU-induced cell growth inhibition in human hepatocellular carcinoma cell line BEL-7402 possibly by down-regulating COX-2 expression and inhibiting PGE2 release.
Collapse